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Background: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin
anticoagulation. Recently, infection has been implicated in the development of HIT.
Case presentation: We herein present a case of HIT diagnosed by a repeated functional assay. A 67-year-old
female with diabetic nephropathy was admitted to our hospital with hypoxemia caused by volume overload. Due
to her diuretic-resistant condition, dialysis therapy anticoagulated with low-molecular-weight heparin (LMWH) was
initiated. The coagulation of the whole extracorporeal blood circuit occurred on day 13. Methicillin-susceptible
Staphylococcus aureus (MSSA) bacteremia derived from a catheter-related bloodstream infection (CRBSI) was
detected on day 15. Based on the hypercoagulable state due to infection, we increased the heparin dose during
dialysis therapy; however, coagulation of the dialysis circuit persisted. We suspected HIT on day 17 in spite of a
normal platelet count and performed a functional assay, which was negative. Since thrombocytopenia subsequently
developed, the functional assay was repeated and a positive result was obtained on day 27, which definitely
established a diagnosis of HIT.
Conclusions: Based on the present clinical course, MSSA bacteremia appears to have contributed to the
pathogenesis of HIT.
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Heparin-induced thrombocytopenia (HIT) is a potentially
critical complication of heparin therapy which results in
thromboembolism. The HIT antibody test is frequently
used to make a diagnosis. However, due to the relatively
high rate of false-positive results, careful evaluations of
clinical features and laboratory examinations are neces-
sary. Therefore, a diagnosis of HIT is challenging, and the
availability of functional assays is indicated. We herein
present a case of HIT triggered by MSSA bacteremia. A
functional assay exhibited the ability to explain the* Correspondence: ydoi@osaka-med.jrc.or.jp
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between HIT and infection.Case presentation
A 67-year-old female with a previous medical history of
diabetic nephropathy was referred to our hospital with
progressive shortness of breath. Her medical history
included type 2 diabetes mellitus, hypertension, and dys-
lipidemia, but no history of heparin administration. Her
medication regimen consisted of amlodipine 10 mg,
cilnidipine 20 mg, telmisartan 80 mg, furosemide 60 mg,
rosuvastatin 5 mg, and febuxostat 20 mg per day. She was
afebrile and hemodynamically stable. She had tachypnea
and SpO2 in room air was 74 %. A physical examination
revealed a gallop rhythm, wheezing on chest auscultation,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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showed the marked enlargement of a cardiac shadow and
bilateral pleural effusion. Laboratory tests revealed severe
renal impairment, and her platelet count (Plt) was normal
at 232,000/μl (Table 1). We diagnosed the patient as
having respiratory failure due to volume overload, and an
intravenous bolus injection of furosemide 100 mg was ad-
ministered with no effect. A drip infusion of carperitide
and oral tolvaptan at 15 mg/day were added. However,
since her condition did not improve, hemodialysis (HD)
therapy anticoagulated with LMWH was initiated on day
3 (Plt 220,000/μl, the first day of heparin exposure)
through the dialysis catheter in the right internal jugular
vein. During non-dialysis periods, the catheter cavity was
locked with unfractionated heparin (UFH). After the initi-
ation of HD, dyspnea gradually resolved, whereas renal
dysfunction worsened. On day 13, the blood circuit of HD
was completely coagulated within 1 h (Plt 310,000/μl, the
11th day of heparin exposure). Since she became febrile
on day 15, empirical intravenous vancomycin for catheter-
related bloodstream infection (CRBSI) was started. CRBSI
was established based on the positive results of a blood
culture for MSSA. On day 16, she developed back pain.
Lumbar MRI revealed pyogenic spondylitis due to CRBSI.
On day 16, the dialysis circuit was completely coagulated
just after the initiation of HD. On the same day, the dialy-
sis catheter in the right jugular vein was removed forTable 1 Laboratory data
CBC
WBC 5930/μl
RBC 320 × 104/μl
Hb 9.1 g/dl
Hct 29.0%















UA 7.4 mg/dlCRBSI. The complete coagulation of the dialysis circuit on
days 13 and 16 was attributed to the hypercoagulable state
derived from infection and not by HIT due to the normal
platelet count. A new dialysis catheter was placed in the
left internal jugular vein because right internal jugular
vein thrombosis was detected. A UFH of 10,000 U/24 h
was administrated systemically against right internal jugu-
lar vein thrombosis. On day 17, the complete coagulation
of the dialysis circuit was detected though the systemic ad-
ministration of UFH and an intravenous bolus (750 U) of
continuous LMWH (450 U/h) for HD. Because the case
in which manifestation of HIT-related thrombosis prior to
a decrease in the platelet count is reported, all forms of
heparin including the locking of the dialysis catheter
lumen were stopped on day 20. On day 21, HD was ac-
complished through anticoagulation with nafamostat
mesilate. HIT was strongly suspected, and the systemic
administration of adjusted argatroban was initiated. On
day 23, a positive result for the HIT antigen assay (latex
agglutination assay) was obtained for a blood specimen
collected on day 17 (optical density 2.0 U/ml, normal
<1 U/ml). In order to make a definite diagnosis, blood
specimens on day 17 (15th day after exposure to heparin)
and day 27 (25th day after exposure to heparin) were ex-
amined by a functional assay (washed platelet activation
assay) [1], and a negative result was obtained for the speci-
men collected on day 17, whereas the result was positive
for that on day 27. The platelet count normalized to
170,000/μl, and warfarin was added to argatroban on day
28. There was no sign of thrombosis, except for thrombus
in the right internal jugular vein. Renal dysfunction im-
proved slowly following the withdrawal of HD therapy.
Regarding pyogenic spondylitis, cefazolin and minomycin
were administered 8 weeks after the confirmation of a
negative blood culture result.
Discussion
HIT is a thrombotic immune-mediated response to
UFH, LMWH, and other polyanions [2]. Regarding the
mechanisms underlying the development of HIT, platelet
factor 4 (PF4) is released on the platelet membrane and
into the bloodstream from the alpha granules of plate-
lets. PF4 is positively charged and may combine with ad-
ministered heparin to form a PF4/heparin complex. This
complex was previously reported to be formed in vitro
at molar ratios of heparin to PF4 of 1:1 to 1:4 [3, 4].
The PF4/heparin complex is recognized as an antigen,
and a PF4/heparin complex antibody (HIT antibody) is
produced, which forms an immune complex with the PF4-
haparin complex; the Fc region of the HIT antibody com-
bines with the FcγIIa receptor on the platelet membrane,
which activates platelets and induces thrombocytopenia [5].
A previous study reported that IgM, IgA, and IgG were al-
most simultaneously elevated around the fifth day after the
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hibited an activation capacity for platelets, monocytes, and
vascular endothelial cells and may be involved in the patho-
genesis of HIT [6]. In the case of intrinsic immune re-
sponses, IgM is produced, a class switch is then stimulated,
and IgG increases 2 weeks later; therefore, the HIT IgG re-
sponse is considered to be atypical [7]. The production of
pathogenic HIT IgG has been proposed as a misdirection
of the immune defense system against negatively charged
microorganisms. When bacterial infection occurs in the hu-
man body, platelets are activated and release positively
charged PF4. PF4 binds charge dependently to various bac-
teria including Staphylococcus aureus [8]. Especially in
gram-negative bacteria, PF4 combines with lipid A and
forms a PF4/bacteria complex [9]. Also PF4 binds to nu-
cleic acids generated from breakdown of bacteria and vi-
ruses, tissue damage, cell apoptosis, and the release from
blood cells such as the formation of neutrophil extracellular
traps [10]. IgG against the PF4/bacteria complex has a de-
fensive function such as the promotion of opsonization
against bacteria and also combines with the PF4/heparin
complex. In other words, when bacterial infection occurs, a
PF4/bacteria complex similar to the PF4/heparin complex
is formed, thereby exposing the PF4/heparin-like epitope
recognized by antibodies which is induced in patients dur-
ing heparin treatments. This theory may explain the forma-
tion of HIT IgG after approximately 5 days in the early
period. In rare cases, HIT was recently shown to develop
incidentally among patients with no history of heparin ad-
ministration [8]. These patients had auto-immune diseases
such as SLE and/or recent microbial infection.
HIT is diagnosed by integrating clinical features and the
results of laboratory examinations. The 4Ts score is typically
utilized in a clinical diagnosis (Table 2) [11]. The 4Ts score
has a prior requirement of thrombocytopenia; however, a
previous study reported that 25% of HIT patients developed
thrombosis 1 to 2 days earlier than thrombocytopenia [12],
and its positive predictive value was relatively low [13]. Anti-
gen and functional assays are used to make the serologicalTable 2 HIT 4Ts score
4Ts category 2 points 1 poin
Thrombocytopenia Platelet count decrease >50 %
and platelet nadir >20 × 109 L−1
Platele
or plat
Timing of the platelet
count decrease
Clear onset days 5–10 or platelet
decrease <1 day (prior heparin
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Total score ≤3 low probability of HIT, 4–5 intermediate probability of HIT, ≥6 high pdiagnosis of HIT. The antigen assay measures an antigen of
the PF4/heparin complex and PF4/heparin antibody levels.
Although antigen assay is highly sensitive, its specificity is
limited by the detection of HIT IgG in patients who do not
have HIT or non-pathogenic IgM or IgA [14]. The optimal
density (OD) values of enzyme immunoassays may be used
to increase specificity; when the OD value is markedly
higher than the cut-off value, the possibility of HIT is high
[15]. A functional assay is more specific than an enzyme
immunoassay for clinically relevant antibodies (capability of
activating platelets), but is not widely available. Functional
assays exhibit excellent sensitivity and specificity [16, 17].
In the present case, when the hypercoagulable state
was observed, a negative functional assay result, slightly
positive OD value, and the absence of accompanying
thrombocytopenia essentially ruled out HIT on day 17
(15 days after exposure to heparin). The cause of the hy-
percoagulable state may have been CRBSI by MSSA. A
HIT functional assay conducted on day 27 (25 days after
exposure to heparin) was positive, resulting in a definite
diagnosis of HIT. We consider HIT to have developed
around day 21 (19th day of exposure to heparin) because
thrombocytopenia was retrospectively observed in that
period (Fig. 1). Since HIT typically develops 5 to 14 days
after the administration of heparin, its onset was slightly
later in the present case. MSSA bacteremia may have
played a role in this discrepancy in latency. In spite of
the administration of heparin, the pathogenic antigen of
the PF4/heparin complex was not present; MSSA
bacteremia triggered exposure of the pathogenic antigen
through mechanisms such as the activation of platelets,
a change in the PF4/heparin ratio, and the formation of
the MSSA/PF4 complex. This hypothesis may explain
why a diagnosis of HIT was established approximately
1 week after MSSA bacteremia. And this hypothesis is
similar to the mechanism of “resetting the clock”, in
which HIT may develop independently of the typical
time frame following recent catheter or surgical inter-
ventions [18]. For example, a previous study reportedts 0 points
t count decrease 30–50 %
elet nadir 10–19 × 109 L−1
Platelet count decrease <30 %
or platelet nadir <10 × 109 L−1
tent with the day 5–10 decrease,
t clear; onset after day 10,
rease <1 day (prior heparin
re 30–100 days ago)
Platelet count decrease <4 days
without recent heparin exposure







Fig. 1 Clinical course
Sugioka et al. Renal Replacement Therapy  (2016) 2:62 Page 4 of 5that a patient receiving dialysis therapy for 9 years devel-
oped HIT for the first time 5~14 days after surgery [19].
Therefore, more PF4 and nucleic acid may be released
from platelets and damaged tissues due to catheter or
surgical interventions, resulting in changes in the PF4/
heparin ratio and/or form PF4/nucleic acid complexes,
which predisposes a patient to HIT.
Conclusions
We encountered a case of HIT diagnosed by a repeated
functional assay. Recent advances have been achieved in
understanding the pathophysiology of HIT, particularly in
the relationship between HIT and infection. To the best of
our knowledge, this is the first case report to focus on the
relationship between infection and the development of
HIT, as proven using a repeated functional assay.
Abbreviations
CRBSI: Catheter-related bloodstream infection; HD: Hemodialysis;
HIT: Heparin-induced thrombocytopenia; LMWH: Low-molecular-weight
heparin; MSSA: Methicillin-susceptible Staphylococcus aureus; OD: Optimal
density; PF4: Platelet factor 4; Plt: Platelet count; UFH: Unfractionated heparin
Acknowledgements
We are grateful to Dr. Takuma Maeda and Dr. Shigeki Miyata (National Cerebral and
Cardiovascular Center, Japan) for performing the functional assay to diagnose HIT.
Funding
The authors declare that they did not receive any funding.
Availability of data and materials
The data sets supporting the conclusions of this report are included within
the article.
Authors’ contributions
SS wrote the initial draft. YD and AS contributed to the critical revision. SS, YD,
TI, TA, KO, MK, and AS contributed to the interpretation of the pathological
condition. All authors read and approved the final version of the manuscript.Authors’ information
Sayaka Sugioka: Clinical Fellow of the Department of Nephrology
Yohei Doi: Clinical Fellow of the Department of Nephrology
Takeshi Ishihara: Chief of the Department of Clinical Engineering
Tetsuya Arisato: Resident of the Department of Nephrology
Keisuke Osaki: Clinical Fellow of the Department of Nephrology
Masao Koshikawa: Assistant director of the Department of Nephrology
Akira Sugawara: Director of the Department of Nephrology.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for the publication
of this case report and any accompanying images.
Ethics approval and consent to participate
Based on the Ethical Guidelines for Medical and Health Research Involving Human
Subjects in Japan, Ethics approval is not necessary when submitting case reports.
Author details
1Department of Nephrology, Osaka Red Cross Hospital, Osaka, Japan.
2Department of Clinical Engineering, Osaka Red Cross Hospital, Osaka, Japan.
Received: 9 May 2016 Accepted: 21 October 2016
References
1. Maeda T, Noguchi T, Saito S, Yoshioka R, Horibe E, Miyanaga S, et al. Impact
of heparin-induced thrombocytopenia on acute coronary artery thrombosis
in patients undergoing PCI. Thromb Haemost. 2014;112:624–6.
2. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention
of heparin-induced thrombocytopenia. American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest.
2008;133(6 Suppl):340S–80.
3. Greinacher A, Gopinadhan M, Gunther JU, Omer-Adam MA, Strobel U,
Warkentin TE, et al. Close approximation of two platelet factor 4 tetramers
by charge neutralization forms the antigens recognized by HIT antibodies.
Arterioscler Thromb Vasc Biol. 2006;26:2386–93.
4. Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, et al.
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of
heparin-induced thrombocytopenia. Blood. 2005;105:131–8.
5. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, et al.
Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse
Sugioka et al. Renal Replacement Therapy  (2016) 2:62 Page 5 of 5model requires human platelet factor4 and platelet activation through
FcγRIIA. Blood. 2001;98:2442–7.
6. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune
response in heparin-induced thrombocytopenia. Blood. 2009;113:4963–9.
7. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal
profile of the anti-PF4/heparin immune response. Blood. 2009;113:4970–6.
8. Krauel K, Potschke C, Weber C, Kessler W, Furll B, Ittermann T, et al. Platelet
factor 4 binds to bacteria-inducing antibodies cross-reacting with the major
antigen in heparin-induced thrombocytopenia. Blood. 2011;117:1370–8.
9. Krauel K, Weber C, Brandt S, Zahringer U, Mamat U, Greinacher A, et al.
Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/
heparin-like epitopes. Blood. 2012;120:3345–52.
10. Jaax ME, Krauel K, Marschall T, Brandt S, Gansler J, Furll B, et al. Complex
formation with nucleic acids and aptamers alters the antigenic properties of
platelet factor 4. Blood. 2013;122:272–81.
11. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of
pretest clinical score (4T’s) for the diagnosis of heparin-induced
thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–65.
12. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical
features of heparin-induced thrombocytopenia including risk factors for
thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;
94:132–5.
13. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the
4Ts scoring system for heparin-induced thrombocytopenia: a systematic
review and meta-analysis. Blood. 2012;120:4160–7.
14. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373:
1883–4.
15. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative
interpretation of optical density measurements using PF4-dependent
enzyme-immunoassays. J Thromb Haemost. 2008;6:1304–12.
16. Harenberg J, Huhle G, Giese C, Wang LC, Feuring M, Song XH, Hoffmann U.
Determination of serotonin release from platelets by enzyme immunoassay
in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol.
2000;109:182–6.
17. Lee DH, Warkentin TE, Denomme GA, Hayward CPM, Kelton JG. A
diagnostic test for heparin-induced thrombocytopenia: detection of platelet
microparticles using flow cytometry. Br J Haematol. 1996;95:724–31.
18. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In:
Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia.
New York: Marcel Dekker; 2000. p. 43–80.
19. Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic
reaction following parathyroidectomy in a dialysis patient with heparin-
induced thrombocytopenia. Nephrol Dial Transplant. 1997;12:2750–5.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
